Antibody-based Therapeutics for Asthma: Current perspectives
Authors:
- Chirag GalaCGChirag Gala
- SandeepSASandeep
- Suraj H. ShindeSSSuraj H. Shinde
- Abhay H. PandeAPAbhay H. Pande
- Shyam S. SharmaSSShyam S. Sharma
- 2 November 2026
- journal article
- Published by Elsevier in Current Opinion in Pharmacology
Abstract
No abstract availableThis publication has 70 references indexed in Scilit:
- Nanobody-Oligonucleotide Conjugates (NucleoBodies): The Next Frontier in Oligonucleotide TherapyPharmaceutical Research, 2025
- Polyvalency: an emerging trend in the development of clinical antibodiesDrug Discovery Today, 2023
- Recent advances of antibody drug conjugates for clinical applicationsActa Pharmaceutica Sinica B, 2020
- Pharmacological strategies to regain steroid sensitivity in severe asthma and COPDCurrent Opinion in Pharmacology, 2019
- Antibody-drug conjugates: recent advances in conjugation and linker chemistriesProtein & Cell, 2016
- Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil LevelsChest, 2016
- The coming of age of engineered multivalent antibodiesDrug Discovery Today, 2015
- An overview of FDA-approved biologics medicinesDrug Discovery Today, 2015
- The history of monoclonal antibody development - Progress, remaining challenges and future innovationsAnnals of Medicine & Surgery, 2014
- Cysteinyl‐leukotrienes and their receptors in asthma and other inflammatory diseases: Critical update and emerging trendsMedicinal Research Reviews, 2006